Meeting
2020 ASCO Virtual Scientific Program
Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
Authors
Eliza Anne Hawkes
Austin Health and Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
Eliza Anne Hawkes , Kate Manos , Geoffrey Chong , Jodie Palmer , Michael Patrick MacManus , Colm Keane , Andrew Mark Scott , Jake Shortt , David Ritchie , Leonid Churilov , Laura Johnston , Tom Witkowski , Allison Anne Barraclough , Sze Ting Lee , Wendi Lin , Rachel Koldej , Richard Khor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03610061
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS8075)
DOI
10.1200/JCO.2020.38.15_suppl.TPS8075
Abstract #
TPS8075
Poster Bd #
408
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial.
First Author: Damien Pouessel
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2022 ASCO Annual Meeting
Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.
First Author: Steven H. Lin
Poster
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
First Author: Sarah Kim